Drug intelligence / Profile preview

hOMSC

Development stage: Phase 1
Lead developer: Cytora
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intrathecal

Overview

Cytora's hOMSC-based cell therapy is an allogeneic, "off-the-shelf" therapeutic platform utilizing human Oral Mucosa Stem Cells. These cells are a unique population of neural crest-derived stem cells harvested from oral mucosa tissue, known for their safety, potency, and regenerative capabilities. For autoimmune conditions and psoriasis, the therapy leverages the immunomodulatory properties of these stem cells to suppress underlying inflammatory processes and promote tissue healing. The program is currently in preclinical development.

Other names: human Oral Mucosa Stem CellshOMSC-based cell therapy

Beyond the preview

Go deeper on hOMSC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hOMSC.

Explore the full profile